Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.40 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.40 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.40 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.40 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11413599 | 0.80 | ANPEP (0.48) | ANPEPCYP2C9CYP2C19PRMT3CARM1 | |
| SCHEMBL9407476 | 0.80 | ANPEP (0.48) | ANPEPCYP2C9CYP2C19PRMT3CARM1 | |
| SCHEMBL3157256 | 0.79 | MEN1 (0.37) | ALDH1A1 | |
| SCHEMBL31008668 | 0.79 | — | — | |
| SCHEMBL7759803 | 0.76 | ANPEP (0.55) | ANPEPCYP2C9CYP2C19PRMT3CARM1 | |
| SCHEMBL15832886 | 0.76 | CYP2C9 (0.50) | ANPEPCYP2C9CYP2C19PRMT3CARM1 | |
| SCHEMBL13808509 | 0.76 | ANPEP (0.42) | ANPEPCYP2C9CYP2C19PRMT3CARM1 | |
| SCHEMBL15343471 | 0.75 | ESR1 (0.33) | — | |
| SCHEMBL14888003 | 0.74 | ANPEP (0.44) | ANPEPCYP2C9CYP2C19PRMT3CARM1 | |
| SCHEMBL14513336 | 0.74 | ANPEP (0.41) | ANPEPCYP2C9CYP2C19PRMT3CARM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220135552-A1 | PYRROLE DERIVATIVES AS PLK1 INHIBITORS | SENTINEL ONCOLOGY LIMITED (GB) | 2022-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135552-A1 | PYRROLE DERIVATIVES AS PLK1 INHIBITORS | PLK1, CDK1, AURKC | ANPEP 4069/4885CYP2C9 3678/4885CYP2C19 3433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.